There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report), Akero Therapeutics (AKRO – Research Report) and Madrigal Pharmaceuticals (MDGL – Research Report) with bullish sentiments.
Avadel Pharmaceuticals (AVDL)
In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Avadel Pharmaceuticals, with a price target of $29.00. The company’s shares closed last Friday at $16.52.
According to TipRanks.com, Brisebois is ranked 0 out of 5 stars with an average return of
Avadel Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $24.29, which is a 54.0% upside from current levels. In a report issued on May 8, Leerink Partners also reiterated a Buy rating on the stock with a $20.00 price target.
See today’s best-performing stocks on TipRanks >>
Akero Therapeutics (AKRO)
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Akero Therapeutics, with a price target of $60.00. The company’s shares closed last Friday at $19.65.
According to TipRanks.com, Katkhuda is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akero Therapeutics with a $48.22 average price target, representing a 125.9% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $56.00 price target.
Madrigal Pharmaceuticals (MDGL)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $375.00. The company’s shares closed last Friday at $205.25.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $367.93, a 78.3% upside from current levels. In a report issued on May 7, Citi also maintained a Buy rating on the stock with a $382.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $23 from $22 at Craig-Hallum
- Avadel Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright
- Avadel Pharmaceuticals reports Q1 EPS (30c), consensus (21c)
- Is AVDL a Buy, Before Earnings?
- Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
